Wed, September 12, 2012
Tue, September 11, 2012
Mon, September 10, 2012
Sun, September 9, 2012
Fri, September 7, 2012
Thu, September 6, 2012
Wed, September 5, 2012
Tue, September 4, 2012
Mon, September 3, 2012
Sun, September 2, 2012
Sat, September 1, 2012
Fri, August 31, 2012
Thu, August 30, 2012
Wed, August 29, 2012

Transcept Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference


//health-fitness.news-articles.net/content/2012/ .. rodman-renshaw-global-investment-conference.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


Transcept Pharmaceuticals to Present at the Rodman & Renshaw Global Investment... -- POINT RICHMOND, Calif., Sept. 4, 2012 /PRNewswire/ --

Transcept Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference

[ ]
[ ]

POINT RICHMOND, Calif., Sept. 4, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: [ TSPT ]), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced today that Transcept management is scheduled to present at the Rodman & Renshaw Global Investment Conference in New York on September 10, 2012 at 10:25 a.m. ET.

A live audio webcast and replay of this presentation may be accessed at [ http://www.wsw.com/webcast/rrshq22/tspt ] and on the Transcept Investor webpage at [ www.transcept.com ].

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue Pharma holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit [ www.transcept.com ]. For information about Intermezzo, please visit [ www.IntermezzoRx.com ].

Contact:
Transcept Pharmaceuticals, Inc.
Greg Mann
Sr. Director, Corporate Communications
(510) 215-3567
[ gmann@transcept.com ]

SOURCE Transcept Pharmaceuticals, Inc.



[ Back to top ]

RELATED LINKS
[ http://www.transcept.com ]


Publication Contributing Sources